4.68
+6.61%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ironwood Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Ironwood Pharmaceuticals is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IRWD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $296.2m and net income of $24.0m. At that date it held total assets of $396.9m and shareholders' equity of −$261.8m.
We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.
LINZESS® (linaclotide), our commercial product, is the first product approved by the United States Food and Drug Administration, or U.S. FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for the treatment, in the U.S., of irritable bowel syndrome with constipation, or IBS-C, in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation, or CIC, in adults, and functional constipation, or FC, in pediatric patients ages 6-17 years-old. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA® for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Feb 2010
- Employees
- 100
- Website
- ironwoodpharma.com ↗
- Head office
- 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Julie MchughIndependent Chairman of the Board$239,573
- Mr. Thomas MccourtChief Executive Officer, Director, since 2009$6.1m
- Mr. Gregory MartiniChief Financial Officer, Senior Vice President
- Mr. John MinardoSenior Vice President, Chief Legal Officer, Secretary$2.7m
- Ms. Tammi GaskinsSenior Vice President, Chief Commercial Officer
- Dr. Michael ShetzlineSenior Vice President, Chief Medical Officer, Head of Research and Drug Development$2.7m
- Dr. Mark CurrieIndependent Director, since 2002$198,573
- Dr. Alexander DennerIndependent Director$198,557
- Mr. Andrew DreyfusIndependent Director$208,573
- Mr. Jon DuaneIndependent Director$203,573
- Ms. Marla KesslerIndependent Director$198,573
- Ms. Catherine MoukheibirIndependent Director$213,573
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 12
- Social
- 65
- Governance
- 70
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ironwood Pharmaceuticals Inc possesses several strengths that contribute to its success in the market. These strengths include:
Weaknesses
- However, Ironwood Pharmaceuticals Inc also faces certain weaknesses that may hinder its growth and performance in the market, including:
Opportunities
- Ironwood Pharmaceuticals Inc can leverage a number of opportunities to further its growth and success, including:
Threats
- Ironwood Pharmaceuticals Inc should remain aware of certain threats that could impact its business and industry, including:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.